top of page

Botanical Solution raises an additional $7 Million to scale up production of vaccine adjuvants

Investment will be used to scale up the GMP production of the vaccine adjuvant, QS-21, and fulfill the supply agreements with Croda and other Big Pharma companies

Botanical Solution Inc. (BSI), the multiple award-winning innovator of sustainable, highly consistent and cost effective Advanced Botanical Materials, has successfully secured an additional $7 million investment.

“New Biotech Business of the Year Award” Tweet this

Following the announcement of a partnership with Croda to accelerate the production of a green, high quality and pharma spec QS-21 at kilogram scale under GMP standards, the Company has gone further in demonstrating, through internal programs and collaboration with big pharma companies, that its product is biochemically comparable and as immunogenic as the traditional QS-21, obtained from very old soapbark trees that grow predominantly in Chile.

The new investment enables BSI to develop a robust and truly sustainable supply chain for the gold standard vaccine adjuvant QS-21, and boosts the expansion plan for agriculture, which includes the roll out of BSI’s flagship product Quillibrium® in Mexico, Brazil, the US and EU. The successful partnership with Syngenta established since 2019 has produced over 50% YOY growth of effective growers’ adoption of the product in Chile and Peru, accumulating over 100,000 acres treated to date.

The financing round, led by Otter Capital, was joined by the Latin American investors Boldo SpA and Quebec LP controlled by the Casanueva and Saval family offices focused on high tech and pharma investments respectively, among other investors.

BSI is on track to start delivering GMP materials to be used in the development of human vaccines later in the year.

According to CEO Gaston Salinas, “BSI is fortunate to have a strong group of investors who are enthusiastic about our progress and vision to impact multiple industries through our breakthrough technology and truly sustainable products. BSI is in a privileged position to solve major issues affecting the supply chain, cost and sustainability of the vaccine adjuvant QS-21 and addressing major challenges associated with disease control in modern agriculture.”

About BSI Botanical Solution Inc., a Delaware Corporation, has a proprietary platform for sustainable and improved production of consistent, high quality Advanced Botanical Materials (ABM). ABM-01 is the first ABM produced by the company, based on a plant called Quillaja saponaria. ABM-01 is the active ingredient used in two gold standard products, BSI’s biopesticide Quillibrium® and the vaccine adjuvant QS-21, used in a Shingles blockbuster vaccine, a recently launched RSV vaccine and a Malaria vaccine. The Company has received a widespread industry recognition for innovation, winning the “2023 Best Process Innovation Award” from ICIS Chemical Business, the 2022 “New Biotech Business of the Year Award” from BioProtection Forum and the “2022 Product of the Year Award” from S&P Crop Science.

To learn more visit us at

Source: Botanical Solution Inc.


FC Global Strategies enables medical, pharma, healthcare, medical device and healthcare IT companies to achieve their business and financial goals

Since 1979 FC Global Strategies has enabled companies globally to achieve their business and financial objectives.

If your company has business or financial objectives check out:

Medical and Pharma Insider is a program of FC Global Strategies.

Click here to schedule a call to discuss your company's business and financial goals.

FC Global Strategies' Contacts:

North America and Latin America

Jeffrey Friedland (Based in the US)

+1 646 450 8909

The Middle East, North Africa and Eastern Europe

David Krutonog (Based in Israel)

+972 50 974 3429

Southeast Asia, Asia-Pacific, Australia, and New Zealand

Ross Swan (Based in Singapore)

+65 9181 9472

Latin America

Claudio Hebling (Based in Brazil)

+55 19 99377 7482

South Asia

Vincent Paul Joseph (Based in India)

It should be +91 962 620 9090

bottom of page